Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aldezyme
- Development stage
- Unknown
- Lead developer
- Alde Medi Impex
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Aldezyme is a digestive aid syrup formulated with fungal diastase (alpha-amylase) and pepsin. Developed by Alde Medi Impex, it is indicated for the treatment of indigestion, dyspepsia, loss of appetite, and stomach discomfort due to improper food breakdown. Fungal diastase is a starch-degrading enzyme that breaks down complex carbohydrates into simple sugars, facilitating easier absorption. Pepsin is a proteolytic enzyme that hydrolyzes dietary proteins into smaller peptides in the acidic environment of the stomach. Together, these enzymes supplement the body's natural digestive capacity, improving nutrient absorption and relieving symptoms like bloating, flatulence, and abdominal fullness.
- Brand names
- Aldezyme
- Other names
- Aldezyme Syrupdiastase + pepsinfungal diastase + pepsin
Beyond the preview
Go deeper on Aldezyme.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aldezyme.